MDMB-FUBINACA

MDMB-FUBINACA

Systematic (IUPAC) name
methyl (S)-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
Clinical data
Legal status	CA: Schedule II
Identifiers
CAS Number	1715016-77-5
ChemSpider	32741674
Chemical data
Formula	C22H24FN3O3
Molar mass	397.4 g/mol
SMILES O=C(N[C@H](C(OC)=O)C(C)(C)C)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3
InChI InChI=1S/C22H24FN3O3/c1-22(2,3)19(21(28)29-4)24-20(27)18-16-7-5-6-8-17(16)26(25-18)13-14-9-11-15(23)12-10-14/h5-12,19H,13H2,1-4H3,(H,24,27)/t19-/m1/s1 Key:RFCDVEHNYDVCMU-LJQANCHMSA-N

MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB₁ receptor and has been sold online as a designer drug.^[1] Although there is no pharmacological information about MDMB-FUBINACA itself, its benzyl analogue (instead of 4-fluorobenzyl) has been reported to be a potent agonist for the CB₁ receptor (Ki = 0.14 nM, EC₅₀ = 2.42nM).^[2]

Side effects

There have been a large number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold to date.^[3] Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and government reports, and subsequent testing confirmed that at least 1000 hospitalisations and 40 deaths had occurred as a consequence of intoxication by MDMB-FUBINACA as of March 2015.^[4][5][6]

Legal Status

As of October 2015 MDMB-FUBINACA is a controlled substance in Belarus, Russia,^[7] and China.^[8]

See also

• 5F-AB-PINACA
• 5F-ADB
• 5F-AMB
• 5F-APINACA
• AB-FUBINACA
• AB-CHFUPYCA
• AB-CHMINACA
• AB-PINACA
• ADB-CHMINACA
• ADB-FUBINACA
• ADB-PINACA
• ADBICA
• APICA
• APINACA
• APP-FUBINACA
• MDMB-CHMICA
• MDMB-CHMINACA
• PX-3

References

1. "MDMB-FUBINACA". Cayman Chemical. Retrieved 13 July 2015.
2. Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982
3. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (Apr 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry 407: 6301–15. doi:10.1007/s00216-015-8612-7. PMID 25893797.
4. "25 killed, over 700 hospitalized: Cheap ‘Spice’ designer drug causes severe poisoning across Russia". 7 October 2014. Retrieved 13 July 2015.
5. "Выступление председателя ГАК, директора ФСКН России В.П. Иванова на заседании ГАК 6 октября 2014 г.". Federal Drug Control Service of the Russian Federation. 6 October 2014. Retrieved 24 June 2015.
6. I. Bulygina (21 October 2014). "Clinical presentations of intoxication by new psychoactive compound MDMB(N)-Bz-F. Thesis of The II Scientific and Practical Seminar ‘Methodical, Organizational and Law Problems of Chemical and Toxicological Laboratories of Narcological Services’, Moscow". Retrieved 13 July 2015.
7. "Очередная жертва спайса". Federal Drug Control Service of the Russian Federation. 17 March 2015. Retrieved 13 July 2015.
8. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.